A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer

NCT02291614 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

45

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated because of immunogenicity and business decision.

Conditions

GI Adenocarcinoma

Interventions

DRUG: AMG 211

Sponsor

Amgen

Collaborators

[object Object]